Wednesday, July 8, 2015

Chart of the Day Affimed Therapeutics (AFMD)

The Chart of the Day belongs to Affimed Therapeutics (AFMD).  I found the pharmaceutical stock by using Barchart to sort the All Time High list for the stocks having the highest technical buy signals, then used the Flipchart feature to review the charts.  Since the Trend Spotter signaled a buy on 4/9 the stock gained 78.23%.

Affimed Therapeutics B.V. is a clinical-stage biopharmaceutical company. It is focused on discovering and developing cancer immunotherapies. Its product candidates are being developed in the field of immuno-oncology. The Company's TandAbs has the ability to bring NK-cells or T-cells into proximity and trigger a signal cascade that leads to the destruction of cancer cells. Its product pipeline includes AFM13, AFM11 and AFM21. Affimed Therapeutics B.V. is headquartered in Heidelberg, Germany.

technical indicators:
  • Trend Spotter buy signal
  • Above its 20, 50 and 100 day moving averages
  • 7 new highs and up 19.36% in the last month
  • Relative Strength Index 74.21%
  • Barchart computes a technical support level at 13.68
  • Recently traded at 14.49 with a 50 day moving average of 10.54
Fundamental factors:
  • Market Cap $347.47 million
  • Revenue expected to grow 92.10% this year and another 77.40% next year
  • Earnings estimates for the next 5 years have not been projected
  • Wall Street analysts issued 3 strong buy and 1 buy recommendation on the stock
The 20-100 Day MACD Oscillator has been an effective technical trading strategy for this stock.
Please share this article

Man Who First Predicted Greek Bank Deposits Would Be Stolen Now Says Another Terrifying Global Collapse Is Imminent / July 07, 2015
Today the man who first predicted Greek bank deposits would be stolen warned King World News that another terrifying global collapse is imminent.
Another Terrifying Global Collapse Is Imminent
James Turk:  “All we need to do is look around, Eric, to conclude that a financial collapse like we saw in 2008 is rapidly approaching. The writing is all over the wall, and it is there for anyone willing to open their eyes….
“The recent nosedive by Chinese stock prices is a red flag, not to mention real estate prices in that country are hanging from a thread and poised to follow stocks in a tailspin as investors look for liquidity and safety. 
Then of course there is Greece, and more generally, the problems of weak economies and heavy debt loads in the eurozone as well as in other heavily indebted welfare states outside of Europe.
Please share this article

GlaxoSmithKline plc (NYSE: GSK)

GlaxoSmithKline plc creates, discovers, develops, manufactures, and markets pharmaceutical products, including vaccines, over-the-counter medicines, and health-related consumer products worldwide. The company offers pharmaceutical products in the therapeutic areas, including respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, and emesis, dermatology, rare diseases, immuno-inflammation, vaccines, and HIV. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health areas.
Take a look at the 1-year chart of Glaxo (NYSE: GSK) below with my added notations:
1-year chart of Glaxo (NYSE: GSK)
GSK has been trending lower for the past 4 months. Over that time, the stock has formed an important trend line of resistance (red). Any (2) points can start a trend line, but it’s the 3rd test and beyond that confirm its importance. GSK obviously has an important trendline of resistance, which currently sits right around $43. The stock appears to be on its way down to its $40 support (green).

The Tale of the Tape: GSK is currently stuck under a down trending resistance. A break above that resistance should mean higher prices, thus a long trade could be made either then, or on a fall to the $40 support. Short traders might look to enter a trade at the resistance.
Please share this article

Trade of the Day: FB Stock Could Crack $100 Before Year End

Facebook Inc (FB) — With a market cap of nearly $245 billion, Facebook is one of the world’s largest Internet companies.

Capital IQ estimates revenue will increase 37% in 2015 due largely to its advertising business. They note the company is making impressive gains in mobile revenues, which have increased from “limited levels” in Q3 2012 to $2.4 billion in Q1 2015. And they expect overall revenue to increase another 34% in 2016.

Credit Suisse increased its 2015 estimate for adjusted earnings per share (EPS) to $1.93, from a previous estimate of $1.88, on revenue of $16.5 billion. Its analysts have a price target of $106 on FB stock, which is almost 55 times earnings. But they expect the company to earn $5.83 in 2017, which puts their price target at a more modest 18 times earnings. They have an “outperform” rating on FB stock and consider it a top pick for 2015.

Since early 2014, FB stock has maintained an orderly bull channel, advancing from about $55 to a high of over $89 in June. The consistency of its advance is impressive, but all stocks fluctuate and Facebook is no exception.

Support for its long-term trend is at slightly over $80 with solid support at its 50-day moving average at $81.60. An interior bull channel has a support line at $84, and that is where traders should purchase FB stock. The price target for a four-month trade is $100, which would result in a nearly 20% gain. However, investors may wish to hold FB stock for much higher long-term returns.

Please share this article